Bolt Biotherapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Several Vivo Capital entities have reduced their beneficial ownership in Bolt Biotherapeutics, with some now holding 0% of common stock.
NASDAQ
Tang Capital Management and affiliated entities have reduced their beneficial ownership in Bolt Biotherapeutics, Inc. to 3.5% of outstanding common stock.
NASDAQ
Tang Capital Management and its affiliates have reduced their beneficial ownership in Bolt Biotherapeutics, Inc. to 3.5% of common stock.
NASDAQ
SCHEDULE 13G/A: Tang Capital Boosts Stake in Bolt Biotherapeutics to 8.7%
Tang Capital Management and affiliates report an 8.7% beneficial ownership stake in Bolt Biotherapeutics, Inc. following a recent reverse stock split.
NASDAQ
Tang Capital Management, LLC and Kevin Tang, along with affiliated entities, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 9.9% in Bolt Biotherapeutics, Inc.'s common stock.